Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment approach for people with idiopathic large macular holes, which are defects in the central retina affecting vision. This study compares the use of a decellularized human amniotic membrane hydrogel against the currently used inverted internal limiting membrane flap technique. The trial aims to assess which method better promotes hole closure and improves visual outcomes for patients with macular holes larger than 400 micrometers. Participants will undergo one of two surgical procedures involving a 25-gauge pars plana vitrectomy. One group will receive the inverted flap technique, which uses multiple small membrane flaps placed over the hole with gas tamponade. The other group will have the internal limiting membrane peeled completely and the macular hole filled with injectable amniotic membrane hydrogel, followed by gas tamponade. These methods are being studied for their anatomical success and safety over a six-month period. During the trial, participants will be closely monitored through follow-up visits over six months to assess hole closure, visual acuity, retinal layer integrity, eye pressure, and any surgical complications. Various eye imaging and vision tests will help measure these outcomes. The study includes quality checks on the hydrogel to ensure safety before use. Participants will be expected to follow postoperative care instructions, including maintaining a prone position, and attend scheduled visits to support thorough evaluation of the treatments.
Actively Recruiting
Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.
Actively Recruiting
Researchers are evaluating whether starting norepinephrine early with rapid dose adjustments can improve outcomes in adults with septic shock. The trial focuses on reducing 28-day mortality, speeding up shock control, and minimizing fluid needs without raising treatment-related side effects. It compares early norepinephrine use to standard treatment with delayed norepinephrine as needed. Participants will receive either norepinephrine or a placebo infusion within one hour of septic shock diagnosis. The norepinephrine starts at 0.05 mcgkgmin and is adjusted every 15 minutes based on blood pressure, with a maximum dose of 0.15 mcgkgmin. Both groups have rescue norepinephrine available if necessary. Limb ischemia and vital signs are closely monitored for 24 hours during the infusion. Throughout the study, participants receive standard sepsis care including fluids, antibiotics, and organ support. Researchers will monitor clinical outcomes and safety for up to 28 days. Key measures include survival at 28 days, time to shock control, and durations of intensive care, hospital stay, mechanical ventilation, and vasopressor therapy. Safety assessments focus on adverse events like cardiac arrhythmias and pulmonary edema.